APA (7th ed.) Citation

A, S., FY, C., NA, U., R, K., Z, M., MJS, S., . . . JG, J. (2022). Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nature cancer, 3(12), 1513. https://doi.org/10.1038/s43018-022-00466-y

Chicago Style (17th ed.) Citation

A, Shahbandi, et al. "Breast Cancer Cells Survive Chemotherapy by Activating Targetable Immune-modulatory Programs Characterized by PD-L1 or CD80." Nature Cancer 3, no. 12 (2022): 1513. https://doi.org/10.1038/s43018-022-00466-y.

MLA (9th ed.) Citation

A, Shahbandi, et al. "Breast Cancer Cells Survive Chemotherapy by Activating Targetable Immune-modulatory Programs Characterized by PD-L1 or CD80." Nature Cancer, vol. 3, no. 12, 2022, p. 1513, https://doi.org/10.1038/s43018-022-00466-y.